Company profile: Tissue Genesis
1.1 - Company Overview
Company description
- Provider of advanced tissue engineering and cell therapy solutions, offering the Icellator2 automated device to extract adult stem cells from adipose tissue for high-yield SVF cells in about an hour, and the sterile, single-use Cell Icellation Kit for efficient SVF isolation with the Icellator2.
Products and services
- Advanced Cell Biology Flight Hardware: Tissue Genesis engineers advanced cell biology flight hardware, custom-engineered, supporting cell culture modeling for NASA, NIH, and DOD missions on the Space Shuttle and ISS
- Cell Icellation Kit: A sterile single-use kit designed for the Icellator2 that enables efficient isolation of stromal vascular fraction cells from adipose tissue
- Icellator2: An automated, industrial-grade device that extracts adult stem cells from adipose tissue, producing high yields of stromal vascular fraction cells in about an hour
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tissue Genesis
CellProthera
HQ: France
Website
- Description: Provider of autologous CD34+ stem cell therapies and expansion tools: ProtheraCytes® to regenerate damaged tissues, particularly cardiac tissue, after acute myocardial infarction; StemXpand®, an automated device for in vitro CD34+ expansion ensuring consistent quality; and StemPack®, a single-use kit used with StemXpand® for production and expansion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellProthera company profile →
PeproMene Bio
HQ: United States
Website
- Description: Provider of BAFFR-targeted immunotherapies: BAFFR CAR-T cells for B cell malignancies and autoimmune diseases; BAFFR BiTE T cell engagers targeting CD3 and BAFF-R, showing in vitro and in vivo tumor efficacy; and allogeneic BAFFR CAR NK cells offering a potential off-the-shelf treatment option. A virtual, privately funded biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PeproMene Bio company profile →
CellTran
HQ: United Kingdom
Website
- Description: Provider of biotechnology-based cell therapy and wound management products, focused on research and development for tissue regeneration and wound healing. Offers Myskin for difficult-to-heal wounds, Lyphoderm, a hydrophilic gel from freeze-dried lysate of cultured human keratinocytes, and Ulcodress.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellTran company profile →
Asterias Biotherapeutics
HQ: United States
Website
- Description: Provider of regenerative medicine therapeutic product development targeting neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases, including human embryonic stem cell development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asterias Biotherapeutics company profile →
BlueRock Therapeutics
HQ: Canada
Website
- Description: Provider of induced pluripotent stem cell (iPSC) therapies using an industry-leading platform, with programs including bemdaneprocel for Parkinson’s disease, OpCT-001 for primary photoreceptor diseases to restore vision, BR-CM01 to replace damaged heart cells after myocardial infarction or heart failure, and pre-clinical Treg-based therapies for autoimmune disorders; conducts clinical trials to assess safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueRock Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tissue Genesis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tissue Genesis
2.2 - Growth funds investing in similar companies to Tissue Genesis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tissue Genesis
4.2 - Public trading comparable groups for Tissue Genesis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →